Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16951479 | 0.82 | PTGS1 (0.32) | POLBPTGS1PTGS2ALOX5ACHE | |
| SCHEMBL27643701 | 0.81 | PSEN1 (0.35) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16952125 | 0.78 | PSEN1 (0.34) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL800711 | 0.77 | HRH4 (0.40) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL27885774 | 0.74 | PSEN1 (0.34) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24006637 | 0.74 | MEN1 (0.41) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16629395 | 0.74 | MEN1 (0.41) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12869835 | 0.74 | MEN1 (0.41) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL8508123 | 0.73 | POLB (0.35) | POLBPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL25123901 | 0.73 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021096948-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20160375005-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS INC (US) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375005-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | POLB 2082/4885PSEN1 2901/4885PSEN2 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.